Most Awaited Q3 Sale is back. Upto 30% discount on every report.

Soft Tissue Sarcoma Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 April 24
SKU : PH356
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Global Soft Tissue Sarcoma Market is segmented by Disease Type (Local sarcoma, Regional sarcoma, Metastatic sarcoma), by Treatment (Radiation Therapy, Chemotherapy, Targeted therapy, Anti-angiogenesis drugs, and Other Treatments), By End-User (Hospitals, Oncology Centers and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030


Soft Tissue Sarcoma Market Overview

Report on Global Soft Tissue Sarcoma by DataM Intelligence estimates the market to grow at a CAGR 8.8% during the forecast period 2023-2030.  Demand from Hospitals, and Oncology Centers in North America is booming. Competitive rivalry intensifies with GlaxoSmithKline Plc, Celgene Corporation, Merck KGaA and others operating in the market.

  • Increasing prevalence of soft tissue sarcoma, rising Research and Development activities on drugs and other therapies, are some of the growth factors boosting the growth of the market. Soft tissue sarcoma is a type of cancer that grows from tissues such as nerves, muscles, fats, blood vessels, and thick skin tissues.
  • There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, Kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others. There are several drugs used for the treatment of soft tissue sarcomas such as sunitinib (Sutent), trabectedin (yondelis), sirolimus (Rapamune), bevacizumab (Avastin), doxorubicin (adriamycin), and others.


Soft Tissue Sarcoma Market Scope and Summary



Market CAGR


Segments Covered

 By Disease Type, By Treatment, By End User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America


For more insights - Download Sample


Soft Tissue Sarcoma Market Analysis

  • In Oct 2016, U.S. Food and Drug Administration approved Eli Lilly and Company’s drug Lartruvo (Olaratumab) with Doxorubicin to treat certain types of soft tissue carcinoma.Clinical Trial Analysis:Total Soft Tissue Sarcoma Studies: 1567

  • By Disease Type, the market is segmented into Local sarcoma, Regional sarcoma, and Metastatic sarcoma. By treatment type, the soft tissue sarcoma market is segmented into radiation therapy, targeted therapy, chemotherapy, anti-angiogenesis drugs, and Others.
  • Chemotherapy has the largest market share in the soft tissue sarcoma market. Further, by End-user, the market has been segmented into hospitals, oncology centers, and Others. Hospitals are dominating the global soft tissue sarcoma market during the forecast period due to increasing number of patients getting treatment at hospitals for soft tissue sarcoma and other relevant cancers.

Soft Tissue Sarcoma Geography Shares

  • Geographically, the market is segmented into North America, South America, Europe, Asia-Pacific, and RoW. North America is leading the global soft tissue sarcoma market due to the high prevalence of cancer and soft tissue sarcoma. According to the American Cancer Society, there were more than 11,500 new cases of soft tissue sarcoma were diagnosed in the U.S. in 2014. Asia-Pacific region is also growing due to rising awareness about increasing advanced treatments for cancer.
  • The major players of global Soft Tissue Sarcoma market include GlaxoSmithKline plc, Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG (Genentech), Johnson & Johnson Services, Teva Pharmaceutical Industries Ltd Celgene Corporation, and others.
  • Some recently approved drugs for the treatment of Soft Tissue Sarcoma are:
  •  In June 2018, Taiwan Liposome Company, (TLC), a clinical-stage specialty pharmaceutical company declared the submission of an Investigational New Drug (IND) application with the U. S. FDA to initiate a Phase I/II, open-label, dose-escalation clinical trial of TLC178, a NanoX liposomal formulation of the anticancer drug vinorelbine, in pediatric rhabdomyosarcoma (a type of soft tissue sarcoma) patients.
  • The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.
Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy
Request new version
Who are the key players in Global Soft Tissue Sarcoma Market ?
Major players are Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Pfizer Inc, Johnson & Johnson Services Inc, Teva Pharmaceutical Industries Ltd, Celgene Corporation, Bristol-Myers Squibb Company, Threshold Pharmaceuticals Inc, and Merck KGaA.
Which region controlled the Global Soft Tissue Sarcoma Market during 2023-2030?
North America region Controls and dominates the Global Global Soft Tissue Sarcoma Market.
Related Reports

Tyrosine Kinase Inhibitors Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 April 18
Starting from



Chemotherapy Induced Anemia Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 June 05
Starting from



Chronic Lymphocytic Leukemia Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 May 22
Starting from



Oncolytic Virus Therapy Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2022 December 15
Starting from



Oncology Nutrition Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 May 30
Starting from



Hepatocellular Carcinoma Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 August 07
Starting from